美女免费一级视频在线观看

Even though some of its former component brands date back a decade or so, Lumanity itself remains a relatively new organization. That’s why global practice lead, medical strategy and communications Michael Parisi describes 2023, the year after its formal launch, as focused on “getting people to know us and to love us.”

Lumanity bulked up its capabilities during the year courtesy of a new platform and digital tool. The former, the Omnichannel Network Engagement Experience, is designed to accommodate the needs of medical affairs and product teams. The latter, Pathway, maps a patient’s experience with a disease or condition over time.

“We spent a considerable amount of the year enhancing our capabilities and investing in the business,” Parisi notes, adding that Lumanity also devoted some effort into boosting its own profile. “We’re constantly out trying to elevate our name and awareness of the expanded resources and services we have.”

Lumanity saw revenue jump nearly 20% during 2023, to $128.1 million from $106.9 million in 2022. Head count shrank, from 515 full-timers at the start of the year to 452 at its conclusion.

The revenue jump notwithstanding, Parisi reports the road was slightly rocky. “It was a tough year,” he says frankly. “I don’t want to sit back and say, ‘It was easy,’ because that’s absolutely not the case. This is probably the trickiest time in this marketplace that I’ve ever seen.”

He attributes the elevated layer of difficulty in large part to the adoption of AI and other next-gen technologies that are “moving at hyperspeed” — and with only a handful of individuals truly capable of harnessing them capably.

“From our perspective as a service provider, the adoption of certain skills and services is not a straight uptick,” Parisi explains. “There’s a lot of education and moving swiftly — but with caution.”

Parisi is equally keen to discuss the expanding scope of Lumanity’s client work. He points to a media program for Indivior’s Opvee, an opioid reversal agent nasal spray approved by the Food and Drug Administration in May 2023. The effort involved developing what Parisi calls “a new playbook to reach audiences that were deemed unreachable.” Campaign targets included physicians and members of police departments and correctional facilities.

“It was one of the most complex media launches I’ve ever worked on, and the one I’m most passionate about because of the size of this challenge to our country,” adds head of engagement Jackie Singley.

As for the future, look for Lumanity to reinforce its branding as an organization able to manage and drive sublime levels of patient advocacy and engagement. “What we’re seeing in the market is a reflection that the patient as a stakeholder is finally being recognized,” Parisi stresses.

Lumanity also hopes to dive deeper into the high-science realms of cell and gene therapies.

“As storytellers and creators, we love that the science is getting more complicated and the data is getting deeper,” Parisi adds. “Our job is to simplify that and create beautiful stories that deliver with impact and motivate audiences to take action.” 

. . .

Work we wish we did

Give Seizures the Sprayer with Valtoco is brilliant in both its execution and its messaging. Using the sprayer device in a provocative manner resonates with anyone who has dealt with epileptic seizures and allows for a connection to multiple audiences. It is inspiring to see an idea that delivers on a cultural/colloquial level and celebrates the nasal delivery of a rescue product. Currently, some rescue products are delivered rectally, which can cause embarrassment for those in need of seizure rescue. — Jennifer Rodriguez, head of content and design

Click to see Lumanity’s Agency 100 2023 Profile.

Click here to return to the MM+M Agency 100.